Primary Prevention With Statin Therapy in the Elderly: New Meta-Analyses From the Contemporary JUPITER and HOPE-3 Randomized Trials
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
T he use of statin therapy for secondary prevention is established in all age groups. 1 However, in primary prevention, current cardiovascular guidelines in the United States and Canada describe the role for statin therapy in the elderly as uncertain.To examine this question, we performed a meta-analysis of age-specific outcome data from 2 recent primary prevention statin trials, JUPITER (Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) 2 and HOPE-3 (Heart Outcomes Prevention Evaluation). 3We combined new subgroup data from these contemporary trials using a fixed-effect meta-analysis with inverse variance weighting of the log hazard ratios by age group (<65, 65-<70, and ≥70 years) using the meta package in R (R version 3.2.3).The pooled treatment effect within each subgroup was estimated, as was the between-subgroup heterogeneity statistic, Q.The JUPITER trial, published in 2008, evaluated rosuvastatin 20 mg daily among 17 802 men and women free of cardiovascular disease with low-density lipoprotein cholesterol levels <130 mg/dL and high-sensitivity C-reactive protein levels >2 mg/L. 2 For the end point of hard atherosclerotic cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death), the JUPITER trial overall reported a 47% reduction in risk (hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.40-0.69;P<0.0001), as well as a 20% reduction in all-cause mortality (HR, 0.80; 95% CI, 0.67-0.97;P=0.02).As shown in the Figure (top), for the 5695 JUPITER participants ≥70 years of age, a comparable 39% reduction in risk was found for this combined cardiovascular end point (HR, 0.61; 95% CI, 0.43-0.86;P=0.004); a nonsignificant 20% reduction in all-cause mortality in this age strata (HR, 0.80; 95% CI, 0.62-1.0;P=0.09) was previously reported. 4These elderly participants, representing 32% of the total JUPITER population, suffered 55% of all the hard atherosclerotic cardiovascular events occurring in the trial.In JUPITER, effects were consistent across age groups, and a formal test for heterogeneity was nonsignificant.Rates of drug withdrawal in the rosuvastatin groups were 14.3%, 17.0%, and 21.6% among those <65, 65 to <70, and ≥70 years of age, respectively.The HOPE-3 trial, published in 2016, evaluated rosuvastatin 10 mg daily among 12 705 men and women free of cardiovascular disease who were at intermediate risk. 3For the identical end point of hard atherosclerotic cardiovascular events, the HOPE-3 trial overall reported a 24% reduction in risk (HR, 0.76; 95% CI, 0.64-0.91;P=0.002) and a 7% nonsignificant reduction in all-cause mortality (HR, 0.93; 95% CI, 0.80-1.08;P=0.32).As also shown in the Figure (top), for the 3086 HOPE-3 participants ≥70 years of age, a comparable nonsignificant 17% reduction in risk was found for the combined cardiovascular end point (HR, 0.83; 95% CI, 0.64-1.07;P=0.16), as well as a comparable nonsignificant 9% reduction in all-cause mortality (HR, 0.91; 95% CI, 0.73-1.13;P=0.38).In HOPE-3, those ≥70 years of age represented 24% of the total trial population yet suffered 43% of all the hard atherosclerotic cardiovascular events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · cited 2×
“To examine this question, we performed a meta-analysis of age-specific outcome data from two recent primary prevention statin trials, the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)(2) and the Heart Outcomes Prevention Evaluation (HOPE-3)(3).”
MethodSelf-citationInterpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Self-citationCholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600176 · Cited by 848
Self-citationGlynn, R. J., Koenig, W., Nordestgaard, B. G., Shepherd, J., & Ridker, P. M. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-8-201004200-00005 · Cited by 252
Self-citationBenefits of Statins in Elderly Subjects Without Established Cardiovascular Disease
Savarese, G., Gotto, A. M., Paolillo, S., D'Amore, C., Losco, T., Musella, F., Scala, O., Marciano, C., Ruggiero, D., Marsico, F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.069 · Cited by 219
Cited by
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000624 · Cited by 907
Feinstein, M. J., Hsue, P. Y., Benjamin, L. A., Bloomfield, G. S., Currier, J. S., Freiberg, M. S., Grinspoon, S. K., Levin, J., Longenecker, C. T., Post, W. S., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000695 · Cited by 658
Metadata
- Authors
- Ridker, P. M., Lonn, E., Paynter, N. P., Glynn, R., & Yusuf, S.
- Venue
- Circulation
- Published
- 2017-05-16
- Volume
- 135
- Issue
- 20
- Pages
- 1979-1981
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2604860179
- Cited by
- 139
- References
- 5
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.